Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or...
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
About this item
Full title
Author / Creator
Gerstein, H C , Yusuf, S , Bosch, J , Pogue, J , Sheridan, P , Dinccag, N , Hanefeld, M , Hoogwerf, B , Laakso, M , Mohan, V , Shaw, J , Zinman, B , Holman, R R , The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators and DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators
Publisher
London: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion. The aim of this study was to assess prospectively the drug's ability to prevent type 2 diabetes in individuals at high risk of developing the condition.
5269 adults aged 30 years or more with impaired fasting glucose or impaired glucose tol...
Alternative Titles
Full title
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
Authors, Artists and Contributors
Author / Creator
Yusuf, S
Bosch, J
Pogue, J
Sheridan, P
Dinccag, N
Hanefeld, M
Hoogwerf, B
Laakso, M
Mohan, V
Shaw, J
Zinman, B
Holman, R R
The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_68890156
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_68890156
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(06)69420-8
